Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 755037-03-7 | Product Number: R0142
Regorafenib
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 25MG |
$117.00
|
Contact Us | 1 | ≥40 |
|
| 100MG |
$245.00
|
1 | Contact Us | 25 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | R0142 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__1__5ClF__4N__4O__3 = 482.82 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (<0°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 755037-03-7 |
| Reaxys Registry Number | 14359949 |
| PubChem Substance ID | 354334233 |
| MDL Number | MFCD16038047 |
Specifications
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Elemental analysis(Nitrogen) | 11.00 to 12.20 % |
Properties (reference)
| Melting Point | 208 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
Transport Information:
| HS Number | 2933.39.4100 |
Application
Regorafenib: A Multikinase Inhibitor of Tumour Angiogenesis, Oncogenesis and the Tumour Microenvironment
Regorafenib (BAY 73-4506) is a potent diphenylurea multikinase inhibitor of tumour angiogenesis (VEGFR1，VEGFR2，VEGFR3，TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), and the tumour microenvironment (PDGFR-β, FGFR). Regorafenib has promising antineoplastic activity in various tumor types. Regorafenib is mainly metabolized by CYP3A4, and the major human metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) are reported to exhibited similar efficacies compared to regorafenib in in vitro and in vivo models. For your reference, [A2979] is a key synthetic intermediate of regorafenib. (The product is for research purpose only.)
References
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- Regorafenib for cancer (a review)
- Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
- A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
- Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.